TrialCNS drugs2024

Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study.

Stewart J Tepper et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.